Clinical trial NCT04907409: Home OCT Fluid Visualization Agreement Study
Official title: Home OCT Fluid Visualization Agreement Study at Multiple Retinal Clinics With Placement of One Home OCT Device in the Home of Each NV-AMD Subject in the US for 5 Weeks
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Neovascular Age-related Macular Degeneration
Lead sponsor: Notal Vision Inc.
Sponsor class: INDUSTRY
First posted: 2021-05-28
Enrollment: 120
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult subjects diagnosed with neovascular age-related macular degeneration (NV-AMD) in at least one eye at the time of enrollment.

Brief summary: This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with scheduled in-office examinations at Week 1, Week 5 and Interim Visits, when applicable, with additional in-office Cirrus volume scans acquired at these office visits. The self-imaging data on the NVHO will be automatically uploaded to the Notal Health Cloud and from there the reconstructed volume scans will sent to the study database.

Detailed description: The objectives of this study are to (1) evaluate the agreement, via positive percent agreement (PPA) and negative percent agreement (NPA), between OCT images captured by the NVHO and by the Zeiss Cirrus HD-OCT in the visualization of fluid as identified by a RC, in the central 10 degrees of the macula of NV-AMD patients, and (2) evaluate the ability of subjects diagnosed with NV-AMD to set up the device and self-image their eyes at home with the NVHO device (rate of successful imaging attempts).Description of Study Visits and Procedures:

Enrollment Visit:

At this visit, the exams will be conducted in the following order:

1. Subject will be informed concerning the study and sign the Informed Consent Form (ICF) prior to the conduct of any study procedures.
2. The following data will be collected for each study subject:

   1. Subject's date of birth (DOB) (if allowed) or age
   2. Gender
   3. Race
   4. Ethnicity
   5. Level of education
3. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma), will be performed on both eyes on the day of the visit.
4. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mm X 6mm, 512 X 128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
5. One or both eye(s) of the subject that meets all screening criteria, including having a diagnosis of NV-AMD in at least one eye previously or at the enrolment visit, will be enrolled in the study.

   * Subjects who do not meet all screening criteria will be deemed a screen failure and will be exited from the study.
   * Study eyes enrolled with fluid in the primary study eye, may receive treatment during the Week 1 Visit.
   * If in the investigator's opinion, the treatment cannot be delayed by approximately 7 days until the Week 1 visit, the subject will be exited from the study as a Screen Failure.

   NOTE: For the subjects with both eyes with NV-AMD, one eye will be randomly selected as the primary eye during enrollment and the other will be the secondary eye. For subjects with only one eye with NV-AMD, the fellow eye with dry AMD may be enrolled. For such subjects, the NV-AMD eye will be the primary eye and the other eye will be the secondary eye.
6. The following data will be collected for the study eye:

   1. Qualifying diagnosis for the study eye from the subject's medical record
   2. From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:

   i. Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings
7. The subject will receive a general overview (including a description of the device and a review of the NVHO set-up guide) of the self-operation of the NVHO device at the investigational clinic facility by trained study personnel.
8. The subject will be (1) reminded that the NVHO device will be delivered to their home and (2) instructed to self-image the study eye(s) once daily using a NVHO device at home for 5 weeks and the Week 1 and Week 5 visits will be scheduled.
9. Collect AEs, if applicable.

Home Set-up with Remote Assistance (NVHO Setup Period)

Following confirmation of subject eligibility at the Enrollment Visit and the subject is enrolled in the study:

1. The subject will be contacted by the NVDC to verify their delivery address.
2. The device will be delivered to the subject's home, with confirmation sent back to the NVDC.
3. Remote support is available by the Notal Vision Diagnostic Clinic (NVDC) via phone during normal business hours, if needed.
4. The subject will follow the steps detailed in the Set-up Guide included in the box. This is considered NVHO Setup Period.

   Note: A care giver, family member or friend is allowed to assist. At most four additional calibrations can be performed, on the same day or different consecutive days, for each study eye if the calibration is not successful.

   Note: If an eye cannot calibrate during 5 separate attempts, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
5. Collect AEs, if applicable.

In-Home Phase (Day 1 to Day 35 post NVHO Setup Period) Following set-up of the NVHO,

1. Day 1: The subject will perform the first self-imaging session with the NVHO device on both eyes followed by automated transmission of the scans. This first session will be considered a practice session.
2. Days 2-35: The subject will perform one self-imaging session each day on the study eye(s) with the NVHO device followed by automated transmission. Each scan has a reliability score provided by the NVHO.

   Note: If an eye fails to self-image five consecutive times, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
3. Collect AEs, if applicable, as reported by telephone call or office visit to the investigational site.

Week 1 (Post NVHO Setup Period)

Subjects will return to the clinic for an office visit one week after the NVHO Setup Period (Home Set-up). The sponsor will provide transportation upon request. At this visit, the exams will be conducted in the following order:

1. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
2. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
3. Initiate standard of care and treatment, if necessary.
4. Collect AEs, if applicable. Week 5 / Exit (Post NVHO Setup Period)

Subjects will return to the clinic for an office visit five weeks after the NVHO Setup Period (Home Set-up). At this visit, the exams will be conducted in the following order:

1. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
2. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
3. Initiate standard of care and treatment, if necessary.
4. Collect AEs, if applicable.
5. Exit subject from the study.

Eligibility criteria: Inclusion Criteria:

1. Subjects must have the ability to speak, read and understand English.
2. Ability to understand and agree to contents of informed consent either in writing or verbally.
3. Age 55 or older at the Enrollment Visit.
4. Adults diagnosed with NV-AMD in at least one eye based on the subject's medical record. Fellow eyes diagnosed with dry AMD may be included as secondary eyes to a primary eye diagnosed with NV-AMD.

   Note: eyes whit other pathologies including pseudocysts, outer retinal tabulations, pigments epithelial, detachments, hemorrhage, sub retinal hyper reflective material (SHRM), geographic atrophy and sub RPE, hypo reflective areas can be enrolled.
5. Best corrected Visual Acuity of 20/320 or better in eyes that will perform self-imaging.
6. Available and willing to set up a device and conduct self-imaging at their home.

Exclusion Criteria:

1. Anti-VEGF treatment for NV-AMD in the study eye(s) at the screening visit.
2. Any other retinal disease requiring steroidal or anti-VEGF injections.
3. Prior experience with the NVHO device.

Primary outcomes:
measure: Positive percent agreement
timeFrame: 1 month following reading center grading completion
measure: Negative percent agreement
timeFrame: 1 month following reading center grading completion
measure: Percentage of subjects who successfully completed the setup of the NVHO device
timeFrame: 5-10 minutes
measure: Percentage of subjects who Successful completed NVHO self-imaging
timeFrame: 2-3 minutes
Secondary outcomes:
measure: Percentage of all sessions that were transmission successfully
timeFrame: 10-15 minutes
measure: Percentage of sessions containing self-imaging that were transmitted successfully
timeFrame: 10-15 minutes
Other outcomes:
Locations:
city: Marietta
country: United States
facility: Georgia Retina
state: Georgia
city: Lexington
country: United States
facility: Retina Associates of Kentucky
state: Kentucky
city: Glen Burnie
country: United States
facility: Elman Retina Group, P.A.
state: Maryland
city: Boston
country: United States
facility: Ophthalmic Cons. of Boston
state: Massachusetts
city: Chesterfield
country: United States
facility: Pepose Vision Institute/Midwest Vision Research Foundation
state: Missouri
city: Norfolk
country: United States
facility: Wagner Macula & Retina Center
state: Virginia
city: Richmond
country: United States
facility: Virginia Eye Institute
state: Virginia
Study officials:
affiliation: Druyanov 5, Tel Aviv Israel
name: Gidi Benyamini, MD
role: STUDY_DIRECTOR
References: